Hu M W, Anne L, Forni T, Gottwald K
Syva Company, Palo Alto, CA 94304.
Ther Drug Monit. 1990 Nov;12(6):562-9. doi: 10.1097/00007691-199011000-00009.
A new reverse-phase high-performance liquid chromatographic (HPLC) procedure has been developed for the quantitation of vancomycin and its crystalline degradation product, CDP-1. The new HPLC procedure involves a liquid-liquid extraction pretreatment procedure and an HPLC internal standard, vitamin B12. The new HPLC procedure was used to measure 50 renally impaired patient samples. Samples were than analyzed by the monoclonal antibody Emit vancomycin assay, and the polyclonal antibody fluorescence polarization immunoassay (FPIA) vancomycin assay, and the results were compared. The Emit vancomycin assay correlated well with HPLC, but FPIA quantitated higher than Emit and HPLC. We conclude that the polyclonal antibody FPIA assay detects CDP-1 in the samples of renally impaired patients, accounting for an average of 10% of the FPIA/Emit bias, and should therefore be used with caution when monitoring vancomycin levels in renally impaired patients.
已开发出一种新的反相高效液相色谱（HPLC）方法，用于定量测定万古霉素及其结晶降解产物CDP-1。新的HPLC方法包括液液萃取预处理步骤和HPLC内标维生素B12。新的HPLC方法用于检测50份肾功能受损患者的样本。随后，样本通过单克隆抗体Emit万古霉素测定法、多克隆抗体荧光偏振免疫测定法（FPIA）万古霉素测定法进行分析，并对结果进行比较。Emit万古霉素测定法与HPLC相关性良好，但FPIA定量结果高于Emit和HPLC。我们得出结论，多克隆抗体FPIA测定法在肾功能受损患者样本中检测到CDP-1，平均占FPIA/Emit偏差的10%，因此在监测肾功能受损患者的万古霉素水平时应谨慎使用。
